MAIA Biotech

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line, with a GAAP EPS of -$0.13 vs. -$0.11 expected. As a clinical-stage biotech, the company reported zero revenue, in line with expectations. R&D expenses surged 81% YoY to $5.6M, driven by Phase 2 (THIO-101) expansion and Phase 3 (THIO-104) initiation. A significant $33M public offering in March 2026 bolstered cash reserves to $27.6M, providing a runway for upcoming clinical milestones despite the widening net loss.